RSS Nuvation Bio's NDA For Taletrectinib Gets FDA Priority Review, Stock Up In Pre-Market

Currently reading:
 RSS Nuvation Bio's NDA For Taletrectinib Gets FDA Priority Review, Stock Up In Pre-Market

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
8,573
Likes
1,923
Credits
33,417©
Cash
0$
Nuvation Bio Inc. (NUVB) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the company's New Drug Application (NDA) for Taletrectinib. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 23 for its decision.

Taletrectinib, an oral investigational and next-generation ROS1 tyrosine kinase inhibitor, is proposed as a treatment for patients diagnosed with advanced ROS1-positive non-small cell lung cancer.

The NDA submission is supported by combined safety and efficacy data derived from the pivotal Phase 2 TRUST-I and TRUST-II clinical trials involving Taletrectinib.

In pre-market trading, Nuvation Bio's shares have risen by 4.43%, currently priced at $2.79 on the New York Stock Exchange.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom